Subscribe now

ON THE plus side, drug treatment for HIV is being refined, AIDS-related
deaths in Britain and the US are falling, and a few months ago doctors started
clinical tests of the much-vaunted Oxford/Nairobi HIV vaccine. So why does so
much gloom still surround HIV? In a nutshell, the worst-affected countries
can’t afford the drugs—and the vaccine is unlikely to work.

In the hardest-hit countries, infection rates have hit catastrophic levels.
In sub-Saharan Africa an estimated 3.8 million people contracted the virus in
2000, bringing the total to more than 25 million.

In South Africa alone, the UN’s joint programme…

Sign up to our weekly newsletter

Receive a weekly dose of discovery in your inbox. We'll also keep you up to date with New Scientist events and special offers.

Sign up

To continue reading, subscribe today with our introductory offers

Piano Exit Overlay Banner Mobile Piano Exit Overlay Banner Desktop